Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Opioid-Induced Constipation Treatment Market Projected To Grow With Significant CAGR Over The Foreca

Author: Ram Reddy
by Ram Reddy
Posted: May 22, 2018

Opioid-Induced Constipation Treatment Market Projected To Grow With Significant CAGR Over The Forecast Period

Opioid-induced constipation treatment are the drugs used for its pain relieving properties in non-cancer and chronic pain. The adverse effects associated with the opioids are decreasing gastrointestinal tract’s motility, making patient’s strain, and making of solid discharges. Furthermore, long-term use of opioids drugs causes harm to the sensory system, limits the release of endogenous opioids such as endorphins. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake. The symptoms associated with the opioid-induced constipation are included dry and hard tools, leathery feeling, painful defecation, bulged abdomen, and loss of appetite.

The opioid-induced constipation treatment market is growing at a significant CAGR due to rise in the aging population using opioid analgesics for chronic pains. Increase in the illicit use of medications, prolonged usage of opioids in the treatment of pain, an increase in the prevalence of cancer is anticipated to boost the global opioid-induced constipation treatment market. In addition to this, launching of newer drugs, growing FDA approvals, positive outcomes in clinical trials, and rise in the healthcare expenditure are expected to propel the opioid induced constipation treatment market. However, lack of awareness regarding opioid induced constipation in patients, the absence of treatment innovations, a high cost of newer pharmaceuticals, adverse effects, including nausea, a risk of heart problems and strokes associated with these drugs and unfavorable reimbursement policies expected to hamper the growth of the opioid-induced constipation treatment market.

Free sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-opioid-induced-constipation-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

The Global opioid-induced constipation treatment market is divided into-

1. Drug type

  • Peripherally restricted?-opioid receptor antagonists
  • Non-selective opioid antagonists
  • opioid receptor antagonists
  • Locally acting chloride channel activators

2. Type of formulation

  • Solids
  • Semi-solids
  • Liquids

3. Route of administration

  • Oral
  • Parenteral (Subcutaneous Injection)

4. End-users

  • Drugstores, retail pharmacies and hospital pharmacies.

Free TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-opioid-induced-constipation-treatment-market/#ulp-c654SbFYO64MsOhu

And lastly, on the basis of geographical regions, global opioid-induced constipation treatment market has been categorized into following five regions-North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America holds the largest share in the opioid-induced constipation treatment market followed by Europe and Asia-Pacific. North America holds the largest share due to expanding the base of opioid-induced constipation patients, according to the American Society of Interventional Pain Physician, in 2013, the U.S. alone was responsible for nearly 80% of the global consumption of opioids. Europe accounts for the significant share in the opioid-induced constipation treatment market owing to increased demand for opioid analgesics in various European countries such as UK, France, Spain, Germany etc. However, growing elderly population in India and China, and rise in healthcare spending are creating the huge growth opportunity for the players in Asia-Pacific region. Apart from that, Latin America and the Middle East are the potential areas for the growth of opioid-induced constipation treatment market because of the increase in opioid-induced constipation sufferers.

Some of the key players in the opioid-induced constipation treatment market are GlaxoSmithKline plc (U.K.), AstraZeneca U.K), Pfizer Inc. (U.S.), SLA Pharma AG (U.K.), AIKO Biotechnology, Inc. (U.S.), Cubist Pharmaceuticals (Merck & Co.) (U.S.), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Bayer AG (Germany), Valeant Pharmaceuticals International Inc. (Canada), Abbott Laboratories (U.S.), Purdue Pharma LP (U.S.) Shionogi Inc. (U.S.) and Cosmo Pharmaceuticals N.V. (Ireland) to name a few. In 2017, FDA approved Symphonic (Naldemedine) for the treatment of opioid-induced constipation, which was manufactured by Purdue Pharma LP and Shionogi. While in 2016, AstraZeneca announced that it has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (Naloxegol) in the European Union (EU) region.

Ask Analyst for Full Information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-opioid-induced-constipation-treatment-market/#ulp-14mlyhjMGhVjZqa3

The global opioid-induced constipation treatment market is in the growing stage, several players are actively engaged in the development of the opioid-induced constipation treatment market products. Major acquisitions and collaborations among companies to commercialize opioid-induced constipation treatment market products to drive the market growth. For instance, in 2015, the co-commercialization agreement for Movenpick signed by AstraZeneca and Daiichi Sankyo, and in October 2014, the entry of Takeda and Sucampo into a global licensing, development, and commercialization agreement for Amitiza are expected to boost the global opioid-induced constipation treatment market. Launching of new products, approval of new drugs from various regulatory bodies, and pipeline products under clinical trials are the key factors helping the growth of the opioid-induced constipation treatment market. For instance, Linaclotide was approved by the FDA in 2012 and by the European Medicines Agency for the treatment in adults with constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-opioid-induced-constipation-treatment-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US):+1-866-598-1553

Website @https://www.precisionbusinessinsights.com

About the Author

Website @ https://www.precisionbusinessinsights.com

Rate this Article
Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Ram Reddy

Ram Reddy

Flag of United Kingdom
United Kingdom

Member since: May 02, 2018
Published articles: 57

Related Articles